However, PD-L1 expression has been found to vary throughout the course of HNSCC, and patients with relapsed disease were advised to have their PD-L1 expression levels re-evaluated (Delafoy et al., 2022). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.